• Aligos Therapeutics began dosing in a Phase 1 trial of ALG-170675, an investigational antisense drug for chronic hepatitis B functional cure.
• No clinical results were reported; initial readouts will come later as the study evaluates safety, tolerability, pharmacokinetics, pharmacodynamics.
• Trial in China is run by partner Amoytop, which holds Greater China rights; single-ascending, multiple-ascending dosing planned in healthy volunteers.
• Move into chronic HBV patients is planned for Q4 2026, positioning the program for potential combination regimens in the region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808965) on August 12, 2026, and is solely responsible for the information contained therein.